Skip to main content
Premium Trial:

Request an Annual Quote

Ariosa Inks Mexico Deal for Harmony Test

NEW YORK (GenomeWeb News) – Ariosa Diagnostics announced today that it has inked a partnership with Advance Medical to offer its Harmony Prenatal Test to clinicians in Mexico.

The San Jose, Calif.-based firm said that Mexico is now one of 46 countries around the world where the Harmony test is available to healthcare providers. The Harrmony test is based on next-generation sequencing technology and provides a direct analysis of cell-free DNA in blood. According to Ariosa, the test has an accuracy rate above 99 percent for evaluating trisomy 21 risk, with a false positive rate of 0.1 percent.

Terms of the agreement with Advance Medical were not disclosed.

Canadian researchers recently said that they will use a C$10.5 million (US$10.2 million) government grant to compare non-invasive prenatal testing techniques for screening for chromosomal conditions such as Down syndrome. Ariosa's Harmony test, which is already available in Canada, was named as the only commercial genomic test involved in that study.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.